标签归档 武汉桑拿按摩论坛

通过admin

Enterprise’s Character: An Analysis of Ruixun’s Financial Fraud from the Perspective of ESG

  On February 1st, 2020, Muddy Waters Research published an 89-page research report, pointing out that Luckin Coffee (hereinafter referred to as "Ruixing"), a Chinese stock company listed on Nasdaq, was fabricating its financial and operational data, saying that "in the third quarter of 2019 and the fourth quarter of 2019, the daily consumption of goods in each store was exaggerated by at least 69% and 88% respectively". On April 2, Ruixing admitted that the fictitious transaction amount was about 2.2 billion yuan, and then its share price plummeted by 80%, and trading was suspended several times during the session. On April 3rd, China Securities Regulatory Commission issued an announcement strongly condemning the financial fraud of Ruixing, saying that it would strictly follow the relevant arrangements of international securities regulatory cooperation, check the relevant situation according to law, resolutely crack down on securities fraud and effectively protect the rights and interests of investors.


  As the old saying goes, "If you don’t keep your word, you won’t stand". The Ruixing incident has had a very serious negative impact on the international reputation of China enterprises, and some investors even have a natural sense of rejection of China Stock Exchange, indirectly contributing to the phenomenon that "bad money drives out good money" in the market recently, affecting employees, supply chains, customers and other stakeholders. From the perspective of ESG, this paper will analyze the various contents of "Ruixing Incident" in detail, and provide warning and reference for regulators, enterprises and investors.


  First, the background of the "Luckin Coffee" financial fraud incident


  (A) the seriousness and negative impact of the Ruixing incident


  1. The credibility of enterprise data in China was questioned.


  The seriousness of financial information fraud is self-evident. This time, Luckin Coffee directly thundered in the US financial market, crushing the international reputation accumulated by China Stock Exchange in one fell swoop and igniting the trust crisis of China enterprises. In the eyes of more overseas investors, they may not know that Ruixing is a case, nor do they know the industry in which Ruixing is located and the business model adopted, but they will stick to the stereotype that this is a China enterprise and a China enterprise with financial fraud as high as 2.2 billion yuan. So how can we judge whether the data of other China enterprises are equally doubtful?


  Based on the principle of information asymmetry, foreign investors will not have a natural trust in China Stock Exchange. On the contrary, China enterprises have to make great efforts to win the favor of investors bit by bit through long-term stable performance level and good corporate governance mechanism. However, Luckin Coffee unscrupulously fabricated a huge transaction amount of up to 2.2 billion yuan, ignoring the law and discipline, and directly sent an extremely negative signal: the credibility of data is insufficient. From good to good, from evil to collapse. The far-reaching impact of "Ruixun Incident" can never be remedied overnight, and the difficulties of China Stock Exchange will only worsen. Even if high-quality enterprises take out powerful third-party forensic materials to endorse and try to prove the authenticity, integrity and effectiveness of their own data, they still need to face the trust stain of "Ruixun Incident".


  At the same time, among the top ten institutional shareholders of Ruixing, there are many famous investment institutions such as Bank of America, UBS and Melvin Capital Management Company. Among the funds with heavy positions in Luckin Coffee, there are also internationally renowned asset management companies such as American Funds and BlackRock. The occurrence of this "Ruixing incident" will seriously affect the trust of investors in top asset management institutions in China’s corporate data, leading to incalculable consequences.


  2. Directly infringe upon the basic rights and interests of stakeholders.


  First, it will directly infringe on the basic rights and interests of employees and consumers. By December 31, 2019, there were 4,507 directly operated stores in Luckin Coffee with tens of thousands of employees. The follow-up progress of the "Ruixing incident" is not optimistic. If it really involves delisting, insolvency or even bankruptcy liquidation, employees will be forced to bear the risk of unemployment at first, and consumers who have prepaid money (such as recharging) will find it more difficult to recover losses. In addition, on the moral and emotional level, Ruixing directly trampled on the trust of employees and consumers, causing bad social impact.


  Second, it will endanger the basic rights and interests of investors. Wind data shows that by the end of 2019, there were 158 institutional investors holding Luckin Coffee shares, with a total of 460 million shares, accounting for 23.93% of institutional shares. At the same time, as shown in Table 1, as of April 8, 2020, the total market value of Ruixing has shrunk from 66 billion yuan at the end of 2019 to 7.84 billion yuan, a cliff-like decrease of 88.12%; The market value of circulation fell to 3 billion yuan, less than one-third of the end of 2019.


企业的品格:从ESG角度分析瑞幸财务造假事件


  Third, the corresponding supply chain enterprises will be hit hard. Luckin Coffee’s supply chain includes Ruixing Baking (Tianjin) Co., Ltd., which was established in May 2019 with a registered capital of 200 million yuan, Swiss coffee maker Shelley and franca, syrup supplier Fabry, dairy supplier Fonterra, coffee raw bean trader Mitsui Products and baking factory Taiwan Province Yuanyou, and Louis Dafu, one of the four major grain merchants. There are a lot of payables in the transaction between suppliers and Ruixing. Judging from the sales scale and the number of stores in Luckin Coffee, there is a risk that the payment cannot be settled in time and comprehensively. "Ruixing incident" not only affects the construction of good supply chain relations, but also directly brings huge financial risks to suppliers. Once Ruixun’s financial fraud event turns into a debt crisis, it will be difficult for suppliers to directly circulate customized equipment and goods in the market (such as Ruixun’s customized coffee machine and product packaging, etc.), which may involve huge economic losses.


  (B) the basic logic of financial fraud in the Ruixing incident


  1. Ruixun’s information disclosure is seriously distorted, and the financial audit mechanism fails.


  From the second quarter to the fourth quarter of 2019, Ruixing executives and some employees forged transactions worth about 2.2 billion yuan. As of April 8, 2020, according to the quarterly financial information of Ruixun in Wind database, the total operating income of Ruixun in the second and third quarters of 2019 was 910 million yuan and 1.54 billion yuan respectively, and the financial report in the fourth quarter has not been released. The market expects the revenue in the fourth quarter of 2019 to be between 2.1 billion and 2.2 billion yuan. Therefore, the proportion of financial fraud is conservatively estimated to be as high as 48.35%.


  Ruixun’s financial fraud method is still in the investigation stage, but according to the five conclusive evidences and six dangerous signals listed in the "fraud" section of the Muddy Water Report, Ruixun’s financial fraud methods may include, but are not limited to: increasing the pick-up number out of thin air by means of "jumping the number of the pick-up code" and blocking the direct correlation between the pick-up code and the daily order volume, thus increasing the online order volume by 72%; Providing free beverage coupons to existing users to invisibly increase the promotion, while falsely claiming that the proportion of free items continues to decline, and the actual sales price has increased by 9% (accounting for the proportion of listed prices); In the third quarter of 2019, the advertising expenditure was exaggerated by 336 million yuan, and there is reason to suspect that it was used for fraudulent income and forged store profits. Ruixing’s financial information disclosure is seriously distorted, and it is difficult to identify it through standardized audit processes and means. Specifically, Muddy Waters Company used a total of 1,510 employees, including 92 full-time employees and 1,418 part-time employees, to visit 981 stores in Luckin Coffee, collect a total of 25,843 shopping receipts, and shoot 11,260 hours of store videos. The time and economic costs are huge, which can never be completed by the basic financial audit mechanism.


  At present, there is no conclusion as to whether Ernst & Young Huaming Certified Public Accountants, which issued the audit report for Ruixing, should bear the responsibility. However, even if the accounting firm has indeed properly fulfilled its expert obligations, the occurrence of the "Ruixing incident" has revealed the natural shortcomings of financial auditing in the face of human fraud and fraud.


  2. Ruixun’s internal control has failed and there are major defects.


  Luckin Coffee’s 2019 prospectus (Form F-1 of the US Securities and Exchange Commission) shows that the audit results of the consolidated financial statements as of December 31, 2018 show that Rui survived two "major defects" in financial and internal control. According to the definition of the standards formulated by the Accounting Oversight Board (PCAOB) of listed companies in the United States, "material defect" refers to a defect or combination of defects in the internal control of financial reports, and there is the possibility that the material misstatement of annual or interim financial statements has not been reasonably and timely prevented or discovered. Ruixing disclosed that it lacked sufficient accounting and financial reporting personnel, necessary knowledge and experience in applying US GAAP and the rules of the Securities and Exchange Commission (SEC), and financial reporting procedures that met US GAAP and the requirements of the Securities and Exchange Commission (SEC).


  Ruixing is a listed Chinese stock company in the United States, which is bound by the Sarbanes-Oxley Act of 2002. Article 404 clearly requires the management to undertake the responsibility of establishing and maintaining a proper internal control structure, and requires listed companies to provide internal control reports and internal control evaluation reports in their annual reports. At present, Ruixing has not disclosed the 2019 financial report and internal control report, but the latest information still cannot confirm that the effectiveness of its internal control has been convincingly improved.


  3. Ruixun’s "investor protection" system is lacking.


  The way of stock pledge financing is to use the securities held as collateral to obtain loans, without the need for management to sell shares directly. However, when the value of pledged shares falls, the lending institution has the right to ask the borrower to provide more cash or collateral, and may ask for compulsory liquidation when the borrower fails to perform. In the face of financial risks, large-scale stock pledge will cause the stock price of the corresponding securities to plummet, which will harm the remaining investors in the market and form a negative cycle, so it is a key negative danger signal for investors. The research report of Muddy Waters shows that the management of Ruixun has mortgaged nearly 50% of its shares as loan collateral (61 million ADS), accounting for 24% of the total shares of Ruixun, even exceeding the total shares (51 million ADS) placed by Ruixun in May 2019 and January 2020, so investors will face serious financial risks.


  Second, the ESG performance level of Luckin Coffee


  (1) Environment (e)


  Ruixing is a new retail professional coffee operator who mainly sells coffee and related drinks, so its production and business operation objects mainly include the whole process of sales and service of coffee drinks. According to the data of American Professional Coffee Association (SCAA), the water polluted by wastewater in the process of coffee water grinding is 40 times as much as that wasted by urban sewers on average. Ruixing has not released a separate social responsibility report, nor has it disclosed its own treatment and recycling methods of sewage and wastewater on the official website. At the same time, the product packaging of coffee catering service industry is also polluted and wasted. As a new retail coffee operator, Ruixing’s take-away service involves more packaging materials than the average catering service. Even if environmental protection kraft paper packaging bags are used, coffee cups still have problems such as degradation and difficulty in direct recycling. At present, there is no direct evidence that it has been punished by the environmental protection department, but the lack of information about the environmental level of Ruixing makes it impossible to carry out relevant environmental assessment, and the real situation is in doubt.


  (2) society (s)


  One of the most important points in Ruixun’s business model and brand proposition is to change the coffee consumption experience with the new retail model. Therefore, Ruixun believes in standardized processes and operating mechanisms more than paying attention to the practical needs of employees, uniting corporate cohesion and shaping common values. Ruixing does not encourage or advocate the communication between employees and customers, but only provides the online purchase method of ordering. With fully automatic coffee machine, each order must be completed within 2 minutes, and the completion process of each preset program needs to be supervised by a special person in the monitoring center. Any illegal operation and delay in operation time will be reflected in the performance evaluation process linked to salary and counted by the digital management system. At the same time, even a number of stores will be arranged in the same community, and there is a competitive situation. On the whole, Ruixun’s social development is not sustainable, and its employees have no sense of belonging and consumers’ loyalty is low, which is directly reflected in the fact that Ruixun still needs to take great efforts to promote sales.


  (C) Corporate Governance (G)


  In terms of organizational structure, Luckin Coffee and Chairman CAR Inc. are both Lu Zhengyao, and its subsidiary, Hydrogen Dynamics Yiwei, reached a strategic cooperation with Luckin Coffee in all-media integration in 2018, involving significant related party transactions. According to the news of Bloomberg on the evening of April 6, Bronstein, Gewirtz & Grossman, a professional class action service agency, announced that it had filed a class action lawsuit against Ruixing and its senior management on behalf of investors, aiming to demand the defendant to compensate for the alleged violation of the Securities Exchange Act of 1934. At the same time, the fourth paragraph of Article 2 of the new Securities Law, which came into effect on March 1, 2020, clearly requires that "securities issuance and trading activities outside People’s Republic of China (PRC) disrupt the market order in People’s Republic of China (PRC) and damage the legitimate rights and interests of domestic investors, they shall be dealt with and investigated for legal responsibility in accordance with the relevant provisions of this Law", and a serious condemnation announcement will be issued for the Ruixing incident, which will resolutely crack down on fraud. Ruixing’s corporate management is bad, its internal control is seriously flawed, and its information disclosure is seriously distorted. The financial fraud of senior executives has involved criminal responsibility including fraud, and it will directly face the early warning risk of delisting.


  Third, the ESG logic behind the Ruixing incident


  (A) the relevance of ESG and financial performance


  ESG integrates environmental, social and governance factors, which can comprehensively reflect the non-financial performance of enterprises and evaluate the long-term sustainable development ability of enterprises. A large number of domestic and foreign literature studies have shown that ESG is related to company valuation, stock returns, financing costs and other factors related to company quality. Cohen et al. (1997) compared the environmental performance and financial performance of manufacturing companies in the S&P500 index, and found that the environmental performance is positively correlated with the intangible assets value of listed companies. This study shows that good environmental performance can increase the valuation of intangible assets of listed companies. In addition to a single environmental factor, Brammer & Millington(2008) discussed the relationship between corporate social performance (CSP) and corporate financial performance (), and found that in the short term, companies with poor CSP performance have better financial performance; But in the long run, companies with good CSP performance have better financial performance.


  In 2018, the Green Finance International Research Institute of Central University of Finance and Economics published two research results, namely, Research on the Correlation between ESG Performance of Listed Companies in China and Corporate Performance, and Research on the Correlation between ESG Performance of Listed Companies in China and Corporate Default Risk, which is also one of the important achievements of the China-UK Green Finance Working Group. It is found that ESG performance in manufacturing industry is positively correlated with the company’s P/B ratio and P/E ratio, while ESG performance is negatively correlated with stock risk, which is particularly significant in manufacturing industry. In terms of ESG and bond default rate, it is found that the higher the ESG level, the lower the probability of corporate bond default or downgrade, and the higher the ESG level, the higher the corporate bond yield.


  At the same time, some scholars suggest that ESG performance has a negative correlation with the company’s downside risks. Koehler and Hespenheide(2013) believe that ESG problems will lead to corporate crises, and those companies that are clearly prepared to deal with ESG shocks can better mitigate short-term and long-term downside risks. Hoepner et al. (2018) found that ESG problems can benefit shareholders by reducing the company’s downside risks.


  (B) ESG is a key indicator to measure the credit quality of enterprises.


  If the financial report maps the current credit ability of the enterprise, then ESG can represent the long-term credit quality of the enterprise. Behind Ruixing’s financial fraud is the lack of ESG performance, which implies the moral responsibility of enterprises. In the case of frequent financial information distortion and financial report fraud, ESG information, as the key motivation information hidden behind the financial performance of enterprises, can make up for the lack of financial indicators and provide investors with evaluation methods and indicators to further understand the overall situation of the company.


  From the specific indicators, environmental indicators can evaluate the green development, environmental compliance and green degree of the whole life cycle of enterprises, which can comprehensively measure the environmental risk and green sustainable development ability of enterprises; Social indicators evaluate the performance of enterprises in public welfare activities and stakeholder protection, measure the degree of responsibility of enterprises from the perspective of stakeholders, and show the operational ability of enterprises from the side; Governance indicators evaluate the organizational structure, investor relations, information transparency, risk management, etc., and carefully consider the corporate governance capacity and long-term sustainable development capacity.


  Fourth, the reference and enlightenment significance of Ruixing incident


  (1) Regulatory body: Establish and improve the ESG information disclosure and verification system of enterprises.


  Basically, in this Ruixun incident, the regulatory authorities need to speed up the construction of ESG information disclosure system, and gradually establish and improve the corresponding auditing system and supporting mechanism. By requiring and guiding enterprises to disclose ESG information, we can help enterprises improve their credit quality and improve the overall quality of Chinese enterprises. At present, there is still a certain gap between the A-share market and the US stock market in the development of ESG information disclosure, and ESG information disclosure has not been completely enforced, which lacks standardization for the performance of listed companies in non-financial indicators. At the same time, although China’s regulatory authorities have increased the regulatory penalties for listed companies in terms of environment and governance in recent years, overall, the cost of violating laws and regulations of enterprises is still lower than that of the US stock market, and the strong binding nature of enterprises’ supervision needs to be further improved.


  In addition, the regulatory authorities should gradually reduce the regulatory barriers in domestic and foreign markets, strengthen the control and supervision of the quality of China Stock Exchange, and strengthen domestic penalties for overseas violations. The new Securities Law, which came into effect on March 1 this year, clearly states that securities issuance and trading activities outside People’s Republic of China (PRC) disrupt the market order in People’s Republic of China (PRC) and damage the legitimate rights and interests of domestic investors, and shall be dealt with and investigated for legal responsibility in accordance with the relevant provisions of this Law. Regarding the Ruixun incident, the statement of China Securities Regulatory Commission on April 3 also stated that the China Securities Regulatory Commission will check the relevant situation in accordance with the relevant arrangements of international securities regulatory cooperation, resolutely crack down on securities fraud and effectively protect the rights and interests of investors.


  (2) Enterprise: issue an ESG consulting rating report reviewed by a third party.


  From the perspective of enterprises, on the one hand, enterprises need to raise awareness of ESG information disclosure and strengthen their own ESG capacity building. Behind the events such as Ruixing in China Stock Exchange, Kangmei and Kangdexin in A-share, the ESG problem of enterprises has been exposed. Only by solving the bad habits of enterprises from the root and improving their credit quality can we avoid the recurrence of such events. On the other hand, enterprises should issue ESG consulting rating reports reviewed by third parties to enhance the credibility of ESG information disclosure data. Enterprises have the motivation to disclose information that is beneficial to them and avoid information that is unfavorable to them, so it is particularly important to issue a credible third-party review of both financial information and ESG information. At the same time, third-party review is also the second constraint on enterprises besides supervision, which can standardize enterprise behavior to a certain extent and enhance the compliance of enterprise information disclosure.


  (C) investors: pay attention to the quality and sustainability of enterprises and avoid speculative business models.


  Investors should also pay more attention to long-term value investment. The strategic mode of short-term investment is short-term and unsustainable. In order to obtain long-term sustainable returns, investors should pay more attention to the internal quality of enterprises and tap the endogenous value of enterprises. By incorporating ESG into the investment strategy, we can not only avoid environmental risks, moral risks and governance risks of enterprises, but also screen out investment targets with strong anti-risk ability and strong self-management ability when systemic risks occur, so as to alleviate the market impact and obtain higher returns. In addition, if more and more investors incorporate ESG information into their investment decisions, they can also close down enterprises to improve ESG performance, thus promoting the high-quality development of the whole market.


  Author:


  Shi Yichen, deputy dean of the International Institute of Green Finance of Central University of Finance and Economics, and dean of the Yangtze River Delta Green Value Investment Institute.


  Yang Chenhui is a researcher at the International Institute of Green Finance of Central University of Finance and Economics, and a researcher at the Yangtze River Delta Green Value Investment Institute.


  Bao Jie is a researcher at the International Institute of Green Finance of Central University of Finance and Economics, and a researcher at the Yangtze River Delta Green Value Investment Institute.


  This article was first published on WeChat WeChat official account: International Research Institute of Green Finance of Central University of Finance and Economics. The content of the article belongs to the author’s personal opinion and does not represent Hexun.com’s position. Investors should operate accordingly, at their own risk.

(Editor: Ma Yan)
通过admin

Big data feels Spring Festival travel rush’s "acceleration" and "flowing China" with strong vitality.

CCTV News:February 16th is the seventh day of the Lunar New Year, and it is also the peak of the return trip. The data shows that today’s railway passenger flow will continue to grow, and we will continue to feel the characteristics and changes of personnel flow through Spring Festival travel rush heat map.

From the first day of the Lunar New Year to the sixth day of the Lunar New Year, the number of passengers who choose to travel by train has increased from 5.5 million to about 15.2 million, which keeps an obvious increase every day, and it has set a new record for one-day railway travel since Spring Festival travel rush this year for two consecutive days.

From the heat map of Spring Festival travel rush on February 16th, the number of trips will continue to increase. The pre-sale data of 12306 shows that the arrival cities with more passenger traffic growth on February 16 are still concentrated in central cities such as Beishangguangshen, Wuhan and Hangzhou.

In some cities, the arrival volume is much larger than the departure volume. On February 16th, the arrival volume of Shanghai, Shenzhen, Dongguan and Ningbo was more than twice the departure volume. From the popular cities of departure, Chengdu East Railway Station has become the railway station with the largest number of departures for three consecutive days, and the speed of outward migration of personnel in the central and western regions is accelerating.

Beishangguangshen is the most popular destination city.

From the travel area, except Guangdong-Hong Kong-Macao Greater Bay Area and the Yangtze River Delta region, the cross-regional personnel flow of several lines from Beijing to Shanghai, Nanning to Guangzhou, Wuhan to Shanghai, Taiyuan to Beijing has increased significantly.

In terms of data for applying for alternate train tickets, Zhengzhou, Guigang, Nanning, Wuhan, Chongqing and other cities are popular starting points for alternate tickets, while Beishangguangshen and Shenzhen are still the most popular destination cities, and the pace of people’s return journey is still accelerating.

29 airports issued mild smog and rain weather warnings.

Fei Changzhun’s weather warning data shows that as of 20: 00 on February 16th, 29 of the more than 260 airports in China issued mild fog, haze and rain weather warnings. Affected by the weather, runways such as Shennongjia Hongping Airport are closed, and Ezhou Huahu Airport has issued a light snow warning. The visibility is less than 1000 meters, and flight delays may occur. Passengers with travel arrangements need to pay attention to flight information updates in time to avoid delays.

通过admin

Announcement of Beijing Local Taxation Bureau and Beijing Environmental Protection Bureau on Issuing the Interim Measures for the Verification and Calculation of Beijing Environmental Protection Tax

No.3 of 2018

  The Interim Measures for the Verification and Calculation of Beijing Environmental Protection Tax are hereby promulgated and shall come into force as of January 1, 2018.

  It is hereby announced.

  Annex: 1. Table of Characteristic Value Coefficient of Sewage Discharge of Some Small Tertiary Industries (omitted)

     2. Water pollution equivalent value of livestock breeding, small enterprises and tertiary industry (omitted)

     3. Adjustment coefficient of dust emission from construction site (omitted)

     4. Construction site dust management grade standard (omitted)

     5. Policy Interpretation on the Announcement of Beijing Municipal Environmental Protection Bureau of Beijing Local Taxation Bureau on Issuing the Interim Measures for the Verification and Calculation of Beijing Environmental Protection Tax (omitted)

  Note: The attachment can be found on the official website of Beijing Local Taxation Bureau (www.tax861.gov.cn).

Beijing Local Taxation Bureau    

Beijing Municipal Environmental Protection Bureau    

March 29, 2018  

Interim Measures of Beijing Municipality on the Verification and Calculation of Environmental Protection Tax

Chapter I General Principles

  the first In order to improve the environmental quality of this Municipality, give full play to the role of taxation in promoting pollution control and emission reduction, and strengthen the collection and management of environmental protection tax, these measures are formulated in accordance with the provisions of People’s Republic of China (PRC) Environmental Protection Tax Law, People’s Republic of China (PRC) Tax Collection and Management Law and its implementation rules and other relevant laws and regulations.

  the second Taxpayers within the scope of this Municipality who cannot calculate the tax payable of air pollutants and water pollutants in accordance with the methods specified in Items 1 to 3 of Article 10 of the People’s Republic of China (PRC) Environmental Protection Tax Law shall verify and calculate the tax payable in accordance with the provisions of these Measures.

  The air pollutants and water pollutants mentioned in the preceding paragraph refer to air and water pollutants discharged by livestock breeding, small enterprises and some tertiary industries, dust (general dust, the same below) generated by construction sites, and sulfur dioxide generated by municipal gas facilities (burning municipal pipeline natural gas).

  Article The local tax authorities at all levels and the competent department of environmental protection shall establish a cooperation mechanism for the verification and calculation of environmental protection tax according to these Measures, and carry out the verification and calculation of environmental protection tax in an orderly manner according to the responsibilities of the departments.

  Article 4 Local tax authorities shall perform the following duties:

  (1) Incorporating taxpayers who meet the approved calculation into tax administration;

  (two) according to the latest pollution characteristic coefficient issued by the competent department of environmental protection, timely maintenance and adjustment of the approved tax-related data;

  (three) to supervise, verify and inspect the basic data of taxpayers’ production and operation, the basic situation of pollutant discharge and the payable amount of environmental protection tax.

  Article 5 The competent department of environmental protection shall perform the following duties:

  (a) the municipal environmental protection department is responsible for formulating and adjusting the sampling measurement methods of this Municipality; To supervise and control the sewage discharge of taxpayers approved for calculation;

  (two) responsible for providing the relevant information obtained in the supervision and management of environmental protection to the district tax authorities;

  (three) to cooperate with the tax authorities to implement the tax inspection of environmental protection tax according to law.

Chapter II Calculation Methods

  Article 6 Taxable amount of pollutants generated by catering industry (without sewage discharge metering equipment), accommodation industry, washing and dyeing service industry (clothing), beauty salon and health care industry, bathing industry (foot washing and bathing), automobile and motorcycle repair and maintenance industry, photography and printing service industry and independent coal-fired boiler that cannot be verified and calculated according to the methods specified in Item 1 to Item 3 of Article 10 of People’s Republic of China (PRC) Environmental Protection Tax Law is:

  Taxable amount = characteristic index value × pollutant discharge characteristic coefficient × specific applicable tax amount

  The characteristic coefficient of emission shall be implemented in accordance with the Table of Characteristic Coefficient of Sewage Discharge of Some Small Tertiary Industries attached to these Measures (see Annex 1). The specific applicable tax amount is the applicable tax amount of taxable pollutants in Beijing.

  Article 7 The taxable amount of water pollutants in livestock breeding, small enterprises, catering and entertainment services (with sewage discharge metering equipment) and hospitals that cannot be calculated according to the methods specified in Items 1 to 3 of Article 10 of People’s Republic of China (PRC) Environmental Protection Tax Law is:

  Taxable amount = pollution equivalent number × specific applicable tax amount

  The pollution equivalent number is calculated by dividing the characteristic value of pollution discharge by the pollution equivalent value, which shall be implemented in accordance with the Water Pollution Equivalent Value of Livestock Breeding, Small Enterprises and Tertiary Industry (see Annex 2) attached to these Measures. The specific applicable tax amount is the applicable tax amount of taxable water pollutants in Beijing.

  Article 8 The taxable amount of dust generated by the construction site of the construction project is:

  Taxable amount = land area of construction site × 0.065 × construction period × adjustment coefficient of dust emission of construction site × specific applicable tax amount.

  The land area of the construction site of the construction project is the land area of the construction unit (including the agent). The construction period shall be calculated on a monthly basis. If the construction period is less than one month, the construction period shall be converted according to the actual construction days in different construction stages divided by the actual days in the current month. The adjustment coefficient of dust emission on the construction site shall be implemented in accordance with the Adjustment Coefficient of Dust Emission on the Construction Site attached to these Measures (see Annex 3). The specific applicable tax amount is the applicable tax amount of taxable air pollutants in Beijing.

  ninthstrip Construction sites include housing construction sites (including industrial plants), decoration sites, municipal infrastructure sites, demolition sites, greening sites, water sites, highway sites, railway sites, etc. within the administrative area of this Municipality.

  Article 10 The construction unit (including the agent) construction land area is determined according to the following methods:

  (a) according to the land, planning, housing and urban-rural construction departments issued by the state-owned land use certificate, the construction project planning conditions from the construction land planning permit (the construction project planning permit from building construction permits), the house ownership certificate or the immovable property certificate, as well as the approval documents of the administrative departments with approval authority or other relevant materials;

  (two) the main technical parameters such as length, width and pipe diameter should be provided when the area of linear projects such as highways, railways, water affairs and pipe networks is approved;

  (three) there is no relevant approval documents to prove the construction area of the project, the construction unit shall calculate the construction area according to the actual land area.

  Article 11 If the construction site of a construction project meets the Class II standard in the Grade Standard for Dust Management of Construction Sites attached to these Measures (see Annex 4) and meets the Class I standard, the tax payable shall be calculated according to the reduction factor of 50%; If it only meets the second-class standard, the tax payable shall be calculated according to the reduction factor of 100%; If the second-class standard is not met, the tax payable shall be calculated according to the reduction factor of 200%.

  If there is grade standard information in the dust management of the relevant government departments in the construction site of the construction project, the tax authorities shall determine the reduction coefficient based on this information.

  Article 12 The taxable amount of sulfur dioxide generated by gas facilities (burning municipal pipeline natural gas) that cannot be actually monitored is:

Taxable amount of sulfur dioxide

Chapter III Approval Methods

  Article 13 Taxpayers who meet the approved calculation conditions should fill in the Basic Information Collection Form of Environmental Protection Tax when registering the tax source of environmental protection tax for the first time, submit it to the competent tax authorities, and be responsible for the authenticity of the application materials.

  Article 14 Taxpayers who implement the approved calculation meet the calculation conditions of taxable pollutants stipulated in Items 1 to 3 of Article 10 of the People’s Republic of China (PRC) Environmental Protection Tax Law by installing, monitoring and measuring the emissions of atmospheric and water pollutants. If these measures are no longer applicable, they should re-fill in the Basic Information Collection Form of Environmental Protection Tax in the next month after the change, and make tax returns according to law.

  Article 15 When taxpayers file tax returns, they shall file and fill in the tax returns according to the following circumstances:

  (1) Taxpayers who are subject to the provisions of Article 12 of these Measures shall fill in the Environmental Protection Tax Declaration Form (Form A) to declare and pay taxes.

  (2) Taxpayers who apply other methods of these Measures shall fill in the Environmental Protection Tax Declaration Form (Form B) to declare and pay taxes.

  Article 16 These Measures shall be interpreted by Beijing Local Taxation Bureau and Beijing Environmental Protection Bureau.

  seventeenthArticle These Measures shall come into force as of January 1, 2018.

通过admin

Pentium pony strives to create a new life with smart driving, which one is more cost-effective?

Although cars can improve the convenience of people’s travel, safety is still an unavoidable topic. Therefore, many car companies have begun to upgrade the safety of their models. Of course, for consumers, a car with complete active and passive safety configurations will be more popular. The richness of a car configuration is related to the user’s car experience, so many people are concerned about its configuration today. Let’s take a look at it next.

First of all, from the appearance, the design style of Pentium pony head has taken a steady route, which is very sporty. Headlights are simple and fashionable, and the design is more fashionable and dynamic. The car is equipped with etc. Coming to the side of the car body, the size of the car body is 3000MM*1510MM*1630MM, and the car adopts simple lines, which gives people a very streamlined feeling. With large-sized thick-walled tires, the shape is eye-catching. In the design of the rear end, the overall shape of the rear end of the Pentium pony echoes the front face, and the taillights look very comfortable and have a rounded shape.

When I came to the Pentium pony car, the interior shape looked very simple and the overall shape was remarkable. The car looks very good outside the steering wheel, made of plastic, showing a sense of atmosphere. Take a look at the central control. The design of the center console is reasonable, which makes the interior style impressive and has a certain sense of science and technology. The dashboard and seats are equally eye-catching. The dashboard of the car presents a simple design style, highlighting the trendy temperament. The car uses fabric seats, which are wrapped in place and are basically enough for daily use.

Pentium pony matching gearbox, 30KW, 90N.m, good power performance.

The car is equipped with Bluetooth /WIFI connection, sunshade mirror, USB interface, uphill assist, rear reversing radar and other configurations, and the configuration performance is passable and basically satisfactory.

After reading the above introduction, let’s make a summary. Such a car with the right price is enough to meet the daily practical needs, and it doesn’t take much thought to maintain it at ordinary times, and the cost performance is good.

通过admin

Is cell therapy reliable in treating cancer? CAR-T leads the world, and 10 popular and emerging cellular immunotherapy show their magical powers!

The incidence of malignant tumor is increasing year by year, which has become a common problem faced by human beings. Traditional treatment methods such as surgery, traditional chemotherapy and radiotherapy have always played a leading role in cancer treatment, but the effects of these treatments are limited. In particular, it is difficult for advanced patients to benefit from these treatments for a long time, nor can they fundamentally solve or change their quality of life. Therefore, researchers are increasingly focusing on the field of immunotherapy. Immunotherapy has brought new opportunities and hopes for the treatment of tumors, among which Immunocheckpoint inhibitors, therapeutic antibodies, tumor vaccines, immunomodulators, adoptive cell therapy, etc. Significantly improved the prognosis of cancer patients, and some patients with advanced cancer obtained long-term survival. In the past two years, many cellular immunotherapy have emerged and developed rapidly, which undoubtedly set off a wave of cancer treatment. So, is cell therapy reliable in treating cancer? In fact, immunotherapy has a history of more than 100 years, and it has only gradually entered the public’s field of vision in the last two years, and it has been absolutely recognized by the world oncology community.   

20731650935352411   

A milestone in the history of cancer immunotherapy In 2013, Science magazine ranked the top ten scientific breakthroughs of the year, and immunotherapy topped the list. In recent years, immunotherapy is one of the hot spots in the research field of tumor treatment at home and abroad, and a large number of clinical studies have shown exciting results. Among them, Cellular immunotherapy uses the self-protection and killing ability of human immune system to achieve anti-tumor effect. Cells with immune function in patients are cultured and proliferated in vitro, and they are given the ability to attack tumor cells by technical means, and then they are imported into patients to realize their own anti-cancer. This therapyAgainst immune cells, not cancer cells.It is not as harmful to the patient’s health as surgery, radiotherapy and chemotherapy. Patients with early cancer can be treated directly, especially with the attack on residual cancer cells after surgery. Judging from the rapid development in scientific research and clinic in recent years, cellular immunotherapy is expected to become the fourth pillar of anticancer therapy in terms of accuracy, effectiveness and safety. Next, the small series of Cancer-free Home gives a general introduction and inventory of a variety of popular and emerging cellular immunotherapy in the biomedical industry, hoping to give cancer friends a general understanding of the general development process of this cancer treatment field. 

0one  CAR-T cell therapy

CAR-T therapy is chimeric antigen receptor T cell immunotherapy, which is a new precise targeted therapy for treating tumors. T cells are activated by genetic engineering technology, and the positioning navigation device CAR (tumor chimeric antigen receptor) is installed to transform the ordinary "warrior" of T cells into "super warrior" CAR-T cells, Specially identify tumor cells in vivo and kill tumor cells efficiently. So as to achieve the purpose of treating malignant tumors. At present, with 2021, Aquilencel injection, Regioscel injection. It was approved for listing in China, in 2022.Cedarchiorense was approved for listing by FDA.CAR-T therapy is expected to enter the blowout period. Indeed, CAR-T technology has shown good curative effect in many hematological tumors, such as leukemia, lymphoma and multiple myeloma, and more than half of hematologic cancer patients who are on the verge of despair and have no cure have achieved good curative effect.  

29751650935353293

CAR-T cell therapy has been listed at home and abroad at present.

Although the clinical effect of CAR-T therapy on solid tumors is not satisfactory, and it has even been sung down by some people, in recent years, CAR-T therapy has made outstanding progress in the fields of gastric cancer, liver cancer and pancreatic cancer. Scholars at home and abroad have made various modifications to CAR-T, and constantly found new targets for the treatment of various solid tumors.    

Clinical study on CAR-T therapy is out of the loop.

0one Gastric cancer and pancreatic cancer As the first CAR-T cell targeting Claudin18.2 in the world, CT041 emerged as early as the ASCO annual meeting in 2019. At that time, the total objective remission rate was 33.3%, which already surprised the world. Now the more remarkable curative effect is undoubtedly the icing on the cake! This clinical data shows a good treatment prospect for digestive system tumors!

Domestic CAR-T therapy CT041 first appeared in ESMO

Developed by Keji Pharmaceutical at the annual meeting of the European Society of Oncology (ESMO) in 2021.Targeting Claudin18.2(CLDN18.2)Autologous CAR-T candidate productsCT041Showing its presenceDigestive system tumorThe outstanding curative effect can be described as brilliant!

The research data is particularly eye-catching!

1. All patients’The objective remission rate was 48.6%, and the disease control rate was 73%.All patients with gastric cancerThe total objective remission rate was 57.1%.

2. Patients with gastric cancer who failed to receive at least 2 lines of treatment in the past:The objective remission rate was 61.1%, and the disease control rate was 83.3%.

3. And the overall tolerance is good!

As of March 3, 2022,CT041 became the first and only CAR-T cell candidate product in the world for the treatment of solid tumors, which entered the confirmatory phase II clinical trial.This is a milestone for CAR-T to conquer the solid tumor field. Congratulations!

In addition, there are many CAR-T cell therapies targeting CLDN18.2.0 2 liver cancer At present, the clinical trial targets of CAR-T in the treatment of liver cancer are mainlyGPC3 (phosphatidylinositol proteoglycan 3). The breakthrough research results completed by Professor Zhai Bo, director of the Department of Tumor Interventions, Renji Hospital affiliated to Shanghai Jiaotong University School of Medicine, were published in the international authoritative journal Clinical Cancer Research on May 5, 2020. By July 24th, 2019, 13 patients had received CAR-GPC3 T cells with a median value of 19.9×108. All the patients are GPC3 positive, and they have received surgical treatment, local treatment or systemic treatment, and they all carry hepatitis B virus (HBV). Two patients achieved partial remission (PR). The 6-month, 1-year and 3-year survival rates of all patients were 50.3%, 42.0% and 10.5% respectively, and the median survival time (OS) was 278 days (39.7 weeks). At the ASCO annual meeting in 2021, Chinese medical researchers published the latest clinical research data of CAR-T drug targeting GPC3 (Ori-CAR-001) in the treatment of recurrent/refractory hepatocellular carcinoma for the first time. As of March 10, 2021, a total of 11 recurrent subjects who received cell infusion were included.All the subjects had advanced hepatocellular carcinoma, and none of them were effective after chemotherapy, TACE (transcatheter arterial chemoembolization) and targeted therapy.Of the 9 evaluable subjects,4 cases achieved partial remission (PR), 3 cases achieved disease stability (SD) and 2 cases developed disease progression (PD).The objective remission rate was 44%, and the disease control rate reached 78%.. 

02  Treatment of tumor infiltrating lymphocytes (TIL)

TILs therapy, simply speaking, is to separate and purify the lymphocytes in the tumor tissue after surgery, select the lymphocytes that can specifically resist cancer, and then amplify and activate them and reinfusion them. This kind of therapy has a history of more than 30 years, and it was first used for malignant melanoma. In recent years, it has given good data in many solid tumors such as cervical cancer and lung cancer.

This therapy is equivalent to pulling back veterans with combat experience directly from the battlefield. After a round of "political review" and "big competition" in professional ability, the spies and traitors are eliminated as far as possible, leaving the ones with the strongest fighting capacity, providing supplies, and then sending them back to the battlefield to continue fighting. Looking at the whole industry, the voice of "innovative therapy based on Tiles cells LN-144 (Lifelecel) is expected to be approved in 2022" is particularly loud. Tiles therapy, as an "ancient" cell therapy, is expected to usher in the first approved product this year, and its great potential in treating solid tumors can not be underestimated, with strong strength and relatively "out of the circle". TILs domain key node event     In 1982  

Steven A.Rosenberg and others discovered for the first time that TILs can inhibit the metastasis of melanoma cells in patients.

  1988  

The earliest attempt of TILs in clinical treatment: TILs therapy for metastatic melanoma achieved an objective remission rate of 60%.

  In 2011  

Steven A.Rosenberg and others published a phase II clinical research data in Clinical Cancer Research: the objective remission rate (ORR) and complete remission rate (CR) of patients with melanoma treated by TILs were 56% and 24% respectively.

  In 2012  

Melinda Bachini, a patient with advanced intrahepatic cholangiocarcinoma, is called the first patient to achieve complete remission (CR) after TILs therapy.

  2019  

At the ASCO meeting, the clinical results of innovative therapies LN-145 and LN-144(Lifileucel) based on TILS cells in the treatment of cervical cancer and melanoma have attracted wide attention in the medical field.FDA awarded LN-145 breakthrough therapy recognition.

  In 2021  

Phase I clinical results of TILs cell therapy at AACR meeting: among 12 evaluable patients.Non-small cell lung cancer patientsMedium,TIL therapy can achieve a total remission rate of 25%, among whichTwo patients achieved lasting complete remission.

  In 2021  

At the annual meeting of tumor immunotherapy association (SITC), the clinical research results of LN-145 in the treatment of metastatic non-small cell lung cancer (mNSCLC) showed that in 28 cases,In patients with recurrent/refractory mNSCLC,After LN-145 monotherapy,The overall remission rate (ORR) was 21.4%(1 case of CR and 5 cases of PR, including 2 cases of PD-L1 negative tumors), 12 cases were stable, and the disease control rate (DCR) was 64.3%.

03  TCR-T therapy

CAR-T cells and TCR-T cells belong to T cells modified by genetic engineering technology.Compared with CAR-T therapy, TCR-T therapy has unique advantages in the field of solid tumor treatment. TCR-T cell therapy can identify tumor-specific antigens from cell membrane surface or intracellular sources, and has entered clinical application from the initial basic immune research, showing initial efficacy in solid tumors, and has become the most likely T cell immunotherapy to make a breakthrough in the field of solid tumors! 

1、 TCR-T cell therapy in China has been approved for clinical use and has become a potential new therapy for HBV-related hepatocellular carcinoma!

At present, in addition to the global TCR-T in full swing in the research and development and clinical verification stage, China is also constantly breaking through innovation.

On December 22nd, 2021, CDE (Drug Evaluation Center) official website was able to inquire about the clinical application of "SCG101 Autologous T Cell Injection", which is a TCR-T cell therapy for specific hepatitis B virus (HBV) epitopes and a potential new therapy for HBV-related hepatocellular carcinoma (HCC).

2881650935354255

▲ Image source: CDE official website

2、 Advanced liver cancer ushered in a new dawn! TCR-T therapy makes cancer patients completely relieved.

As early as 2020 International Hepatology Conference (ILC), ADP-A2AFP, a new TCR-T therapy for liver cancer based on T cells, caused quite a stir, and also made a new breakthrough in the new therapy for liver cancer.

Among the included patients,One patient showed a complete remission (CR) in cancer progression, and the AFP of the other participants also decreased to varying degrees.This means that the experiment has made progress, and it also shows that this therapy is effective for the treatment of advanced liver cancer.

             

10051650935354424

All the 9 patients involved had undergone surgery and conventional radiotherapy and chemotherapy, but failed or became intolerant. Among the 4 patients who received the highest dose of treatment,One patient achieved complete remission, and CT scan showed that all the lesions in the patient disappeared, and it has lasted for more than half a year without any recurrence!

The best response of other patients (cohort 1, cohort 2) is stable. 1 patient in queue 2After one month of treatment, the volume of the primary lesion did not decrease, but the volume of mediastinal lymph node metastasis decreased obviously!       

39351650935354669

Therefore, TCR-T therapy targeting AFP (alpha-fetoprotein) can kill tumor cells expressing AFP. Based on the positive results of this study, researchers are expected to expand the maximum dose to 5 billion cells, and we look forward to the publication of updated data of this study!

04  CAR-NK therapy

In recent two years, in addition to CAR-T therapy, another new cancer cell therapy- Natural killer (NK) cell therapy It has also gradually attracted attention. The researchers said, NK cell As a cell anticancer therapy, it has more potential, and it may be safer, cheaper and faster. CAR-NK is to add a chimeric antibody to NK cells by genetic engineering that can recognize tumor cells and activate NK cells to kill tumor cells at the same time. 

one   The first "spot" CAR-NK clinical trial in China was approved by the Food and Drug Administration. On November 11, 2021, National Medical Products Administration Drug Evaluation Center passed an independent research and development in China. Mesothelin (MSLN) chimeric antigen receptor NK cells (CAR-NK) injection for the treatment of advanced epithelial ovarian cancer. Application for clinical trial of CAR-NK injection. According to the cancer-free home, This product is the first "spot" CAR-NK product of foreign origin in China. This also marks a new milestone in the research of immune cell drugs in the treatment of solid tumors in China! 

2  The 1-year survival rate doubled, and the curative effect of CAR-NK therapy in solid tumor increased sharply.

Recently, the journal Clinical Oncology Research published a phase II clinical trial for lung cancer. Heat shock protein 70(Hsp70) is highly expressed in about 70% of middle and advanced lung cancer. NK cells are activated by Hsp70 in vitro, which is equivalent to making NK cells meet their future enemies in vitro, "making enemies" first, and then returning them to patients, so that NK cells can formally fight with cancer cells in vivo. This method of stimulating NK cells with antigen peptides in vitro and giving them certain specificity is a hot topic in recent years.

A total of 16 patients with stage III non-small cell lung cancer were enrolled in this clinical trial. One group received traditional chemotherapy combined with radiotherapy and chemotherapy, and the other group received chemotherapy combined with Hsp70 pre-stimulated NK cell reinfusion.

The results show that:The one-year survival rate can be doubled from 33% to 67% by Hsp70 pre-stimulated NK cell reinfusion therapy combined with traditional radiotherapy and chemotherapy, and the preliminary results are encouraging.

Next, Xiaobian shows a typical successful case in combination therapy, as shown in the figure:After 1~2 months of treatment, the lung tumor completely disappeared and the curative effect has been maintained for 18 months.

  85441650935355029   

In addition to the above-mentioned clinical studies at home and abroad, CAR-NK cells also have a good effect on glioblastoma and neuroblastoma, specifically recognizing and killing breast cancer cells with high efficiency, and have a remarkable effect on multiple myeloma.

05  Dendritic cell vaccine

Cancer vaccine is a form of immunotherapy, which can prevent cancer from developing or kill existing tumors by stimulating or restoring the human immune system. Dendritic cell (DC) vaccine is a new biological therapy for malignant tumor in recent years, which has been paid more and more attention and recognized by oncologists. As an important member of the human immune defense system, Dendritic cells have the strongest antigen presenting function and are known as "sentinels" of the immune system. It is named because its cells extend outward with many dendritic protrusions. It mainly uses modern high-tech biotechnology to collect the peripheral blood of tumor patients, induce and cultivate a large number of dendritic cells in a short time in vitro, and equip them with immune cells that patients do not have, so as to accurately "target" and kill cancer cells. Not only that, It can also induce immune memory in patients, so that patients can obtain long-term anti-cancer effect.

DCVAC/LuCa is a dendritic cell vaccine developed by the United States for patients with non-small cell lung cancer.In a study on the first-line treatment of advanced lung cancer announced at the ASCO conference in 2019, DCVAC/LuCa vaccine combined with chemotherapy groupThe objective remission rate is 45%,The median overall survival time was 15.5 months, and the median progression-free survival time was 6.74 months.Reduce the risk of death by 46%!

In the Phase II clinical study of the latest novel dendritic cell vaccine DCVAC/LuCa (lung cancer dendritic cell vaccine) combined with standard carboplatin/pemetrexed in the treatment of advanced non-squamous cell (nsq) non-small cell lung cancer in 2022,The 1-year survival rate was 72.73% and the 2-year survival rate was 52.57%.By the time the data was published, the median overall survival time had not been reached. The median progression-free survival time was 8.0 months, and the objective remission rate was 31.82%.

  Prostate cancer-Provenge vaccine  

Provenge is the first vaccine approved for treatment in the United States, which initiated a new era of cancer immunotherapy.This is an autologous cell immunotherapy, which was approved by FDA on April 29, 2010 to treat asymptomatic or mild mCRPC. This approval marks the success of 20 years of unremitting efforts.In the United States, Provenge is the only FDA-approved immunotherapy for prostate cancer made from patients’ own immune cells.

  Ovarian cancer-dcvac/ovca vaccine  

At the 50th annual meeting of the Society of Gynecological Oncology (SGO) in 2019, the final result of SOV02, a phase II clinical trial, was announced: DCVAC/OvCa, an immunotherapy based on dendritic cells, was added to standard carboplatin and gemcitabine schemes for patients with recurrent, platinum-sensitive and epithelial ovarian cancer.It can prolong the overall survival (OS) of patients with advanced recurrent ovarian cancer by more than one year.andDCVAC/OvCa reduced the death risk of second-line treatment of ovarian cancer by 62%. The overall survival (OS) increased significantly by 13.4 months. The median progression-free survival rate (mPFS) increased by 1.8 months. The global phase III study will be launched soon.

Melanoma-TLPLDC vaccine

The subgroup analysis results of the phase IIb clinical trial of TLPLDC vaccine in the treatment of melanoma were published at the ASCO-SITC Clinical Immunooncology Conference in 2020.

In that population analysis follow the clinical research protocol (PT), compared with the comfort unit,The 24-month disease-free survival rate in TLPLDC treatment group was significantly improved (62.9% vs 34.8%), indicating that the relative risk of disease recurrence was reduced by nearly 50%.

In the population analysis of Intentional Treatment (ITT),There was no significant improvement in 24-month disease-free survival between TLPLDC treatment group and placebo group (38.5%) vs 27%),But in this analysis,The improvement trend of 24-month overall survival rate (OS) was stronger (86.4% vs 75.1%)..

  Kidney Cancer-Ilixadencel Vaccine  

Ilixadencel is an allogeneic dendritic cell (DC) vaccine. Research shows that,Ilixadencel combined with targeted anticancer drug sunitinib(Sotan, common name: sunitinib)First-line treatment of newly diagnosed advanced metastatic renal cell carcinoma(mRCC)Compared with patients treated with sunitinib alone, the total remission rate is doubled, the complete remission rate is higher and the remission is more lasting!

  Glioblastoma-AV-GBM-1 vaccine   On June 8, 2021, well-known foreign biomedical companies announced the release of phase II clinical trial data of their personalized cancer vaccine AV-GBM-1. The research shows that this new vaccine has great potential for prolonging the overall survival of newly diagnosed glioblastoma patients in the medium term. The median progression-free survival time of patients was 10.4 months, which was about 50% higher than the median progression-free survival time of 6.9 months in the landmark STUPP study, and established a nursing standard for newly diagnosed glioblastoma patients.     Non-small cell lung cancer-tedopi vaccine  

On April 1st, 2020, a new anti-cancer vaccine, TEDPI, achieved positive results in the phase III clinical trial of non-small cell lung cancer. After the immune checkpoint inhibitor (PD-1) was resistant or failed, all patients in the group used TEDPI vaccine in the second or third line, and the overall survival rate for one year reached 46%, far exceeding the preset 25%!

A 54-year-old patient with advanced lung cancer has rapidly shrunk (from 39mm to 23mm) after five injections of the new lung cancer vaccine. At the time of reporting, his survival time has exceeded 20.6 months, and he is still being followed up.

06  CIK cell therapy

  CIK cells, that is, Cytokine-Induced Killer (CIK), are a new type of immunocompetent cells, which have strong proliferative ability and cytotoxicity, and have certain immune characteristics. Because this cell expresses both CD3 and CD56 membrane protein molecules, it is also called NK cell (natural killer cell)-like T lymphocyte, which has both the strong anti-tumor activity of T lymphocyte and the non-MHC-limited anti-tumor advantage of NK cell. If NK cells are the "first line of defense" to protect human health, then CIK cells are undoubtedly the "precision missiles" to kill tumor cells. Especially for patients after surgery or radiotherapy and chemotherapy, it can eliminate residual tiny metastatic lesions, prevent cancer cells from spreading and recurring, and improve immunity. Therefore, CIK cells are considered as the first choice for a new generation of adoptive cellular immunotherapy for tumors. Research progress of representative CIK cell therapy     

nasal pharyngeal cancer  

Among 137 patients with nasopharyngeal carcinoma treated by CIK, 50% of them improved their survival time by 6-9 months, and among 137 patients treated by CIK, 50% of them delayed their tumor progression by 6-7 months.

32171650935355613

  liver cancer  

Among the 819 patients with liver cancer treated by CIK, 50% of them improved their survival time by 13~25 months, and among the 819 patients treated by CIK, 50% of them delayed their tumor progression by 4~7 months.

87421650935356226

  ovarian cancer  

Among 72 patients with ovarian cancer treated by CIK, 50% of them have improved their survival time by 24 months. Among 72 cases of ovarian cancer treated by CIK, 50% of ovarian cancer patients delayed their tumor progression by 14.5 months.

91721650935356659

 

carcinoma of colon

Among 126 patients with colon cancer treated by CIK, 50% of them have a longer survival time of 30 months. Among 126 patients with colon cancer treated by CIK, 50% of them delayed their tumor progression by 14.5 months.

81471650935357165

  breast cancer  

The probability that the survival time of 150 breast cancer patients treated with CIK can reach 5 years is increased to 85.7%; The probability of keeping breast cancer from recurring in 150 breast cancer patients treated with CIK within 5 years increased to 72.3%.88231650935357798

  Solid tumor  

Of the 31 patients treated with PD-1 antibody combined with DC-CIK, 2 patients’ tumors completely subsided and 5 patients’ tumors partially subsided. Of the above 7 patients, 6 patients’ effects can be maintained for 5 months. The tumors of the other 13 patients remained stable.

13431650935358461

  renal carcinoma  

Among 43 patients with advanced renal cell carcinoma treated by CIK, 50% of them can delay the tumor progression to 14.7 months.

60351650935359231

07  CAR-M therapy 

In recent years, the study of macrophages has also been paid attention to by the industry. How to activate the anti-tumor activity of these macrophages is the direction that immunologists have been working hard. CD47, an immune checkpoint on macrophages, has become a very promising hot target in the field of tumor immunotherapy.

In a recent study published in Nature Biotechnology, researchers from perelman Medical College of the University of Pennsylvania and other research institutions may have an alternative to T cell therapy to overcome these challenges. Their research shows that genetic modification of macrophages (an immune cell that devours intruders in vivo) may be the key to developing effective cell therapy for solid tumors. They were able to confirm these genetically modified expressions. The macrophages of CAR (CAR-M) can kill tumors in human samples and mouse models in the laboratory and prolong their life.   

81441650935359696   

CAR-M therapy is centered on macrophages, which devour invading cells instead of destroying them like T cells. T cells are more like Space Invaders games, while macrophages are more like Pac-Man games. Another major difference between macrophages and T cells is that they are the first responders of the body to virus infection. Historically, this poses a challenge in trying to genetically modify them to attack cancer, because macrophages are not easily transfected by standard viral vectors used in gene therapy and cell therapy.

In this experiment, the research team used genetic engineering technology to transform macrophages. They not only expressed CAR targeting HER2 antigen, but also were activated and differentiated into M1 macrophage types that promoted inflammation. In this way,These CAR-M cells can not only target tumor cells, but also change the microenvironment near tumors by secreting pro-inflammatory cytokines. They can also present tumor antigens to T cells and activate T cells’ immune response to tumors, which can be described as "killing three birds with one stone".

On March 18th, 2021, Carisma Company of the United States announced the completion of the first drug delivery to the subjects of CAR-M therapy (CT-0508) targeting Her2, marking a new era of CAR-M transformation therapy for solid tumors. In a word, taking macrophages as effector cells transformed by CAR is expected to reverse the tumor inhibitory microenvironment, so as to break through the obstacles of immune cell therapy in solid tumors. 

08  CTL (cytotoxic T lymphocyte) therapy

What cell therapy can be used as an adjuvant therapy for the majority of patients with inoperable advanced cancer? In recent years, researchers have been developing new immunotherapy schemes for these patients, including CTL(cytotoxic T lymphocytes) technology. This technology mainly uses protein, which is unique to cancer cells and has no or low content in normal cells, as bait to select the truly anticancer lymphocytes in peripheral blood, and then further improve and amplify them in vitro, and then return them to patients. MTCA-CTL immunotherapy is a new generation of biological immunotherapy model introduced in China. While ensuring the expansion of non-MHC-restricted killer NK-T cells, directional expansion of HC-restricted CD8++specific CTL cells can make its proportion in cell products reach 60% ~ 70%. The combined effect of this killer cell makes the efficiency of killing tumor cells higher.  

10991650935359999

At present, the multi-target compound antigen peptide biological immunotherapy technology, which is undergoing the second phase of clinical trials in the Cancer Hospital of China Academy of Medical Sciences, is the fifth and brand-new generation of cellular immunotherapy technology, which can optimize the activation method of DC (dendritic cells) to enhance the killing effect of immune cells on tumor cells. At present, it has achieved good clinical results and I believe it will really benefit cancer patients.

Mainly suitable for solid tumors.Head and neck tumor, esophageal cancer, lung cancer, gastric cancer, breast cancer, liver cancer, membranous adenocarcinoma, colorectal cancer, ovarian cancer, uterine cancer, coma cancer, prostate cancer, malignant melanoma, sarcoma and partial malignant lymphoma.

If economic conditions permit and you want to consult MTCA-CTL therapy, you can contact.Cancer-free Home Medical Department (400-626-9916), a detailed assessment of the condition.

09  CAR-NKT therapy

  Natural killer T cells (NKT) are a group of special T cell subsets that express both T cell receptors (TCR) and NK cell receptors on the cell surface, and can produce a large number of cytokines. Such as IL-4 and INFγ. These cells can not only directly dissolve and kill tumor cells, but also play an anti-tumor role through indirect ways (secreted cytokines, activated immune cells, etc.). Recently, a phase I clinical trial jointly conducted by Baylor Medical College in Houston and Texas Children’s Hospital is evaluating a new treatment for children with recurrent neuroblastoma –CAR-NKT cell therapy is expected to break through this bottleneck. Phase I trial, code-named GINAKIT2, used CAR-NKT cells for the first time to treat recurrent neuroblastoma. Eleven children (1~21 years old, with an average age of 7 years old) were all recurrent/refractory high-risk neuroblastoma, with extensive metastasis and no better treatment plan in clinic. The results are very encouraging: Of the 11 advanced patients, The condition of 4 patients was stable, 2 patients achieved partial remission (tumor was obviously reduced), and one of them had complete remission (CR) after receiving the second CAR-NKT cell infusion. In safety, CAR-NKT is safer than CAR-T therapy. No dose-limiting toxicity was observed in the first 28 days after infusion. 

10  Compound immune cell therapy

This technology will alsoSix kinds of cells, such as γδT cells, NK cells, NKT cells, killer T cells, dendritic cells and helper T cells.Activate, multiply 10 million to 20 million cells to 2 billion to 5 billion cells, and then inject them into patients. Cultivating such important immune cells at the same time greatly improves the therapeutic effect compared with single treatment.

Except for some leukemia and malignant lymphoma,It can be used for the treatment of most cancers, and has a good effect in refractory cancer types and advanced cancers. Besides,Compound immune cells also play a great role in improving immunity and strengthening the body.

Xiaobian has something to say

In recent years, due to the development of medical level, new cancer treatment methods have appeared one after another, among which cellular immunotherapy is in full swing, which brings new hope to cancer patients. According to the latest statistics, compared with patients with advanced lung cancer, gastric cancer and liver cancer who only receive surgery, radiotherapy and chemotherapy, adjuvant cellular immunotherapy can prolong the survival time of patients and significantly improve the data effect. In fact, tumor treatment is actually a complex "project", and it is difficult to achieve good results by relying solely on a certain treatment method. Tumor treatment needs the cooperation of various treatment methods to achieve the final victory in the fight against cancer. 

通过admin

China released, created a good innovation ecology, and promoted medical technology to better serve people’s lives and health.

China Network April 17 (Reporter Zhang Yanling) Health is an inevitable requirement to promote people’s all-round development, and it is also an important symbol of national prosperity and national prosperity. With the rapid development of economy, society and human civilization, health has become the first demand of the people after China has built a well-off society and solved the problem of food and clothing. The CPC Central Committee attaches great importance to scientific and technological innovation and puts forward that science and technology should "face people’s lives and health".

On April 15th, 2023 China Medical Development Conference was held in Beijing.

Medical science and technology is closely related to people’s health and social well-being, and it is a key factor to promote human health. In order to better serve people’s lives and health, medical science and technology must be innovated, and innovation needs to create a good ecology. So, how to create a good ecology of medical science and technology innovation? On April 15th, at the 2023 China Medical Development Conference held by China Academy of Medical Sciences, the participants discussed the construction of national medical science and technology innovation system and the strategy of creating a good ecology.

Chen Zhu, vice-chairman of the Standing Committee of the 13th National People’s Congress, president of China Red Cross Society and academician of China Academy of Sciences, believes that we should focus on helping to build a healthy China, improving people’s health and well-being, identify the frontiers of medical health science and technology, actively explore the road of new medical education reform, promote the transformation of discipline layout, resource allocation and scientific research ecology, build a good innovative ecology, and make overall plans for innovative layout, so as to contribute wisdom to accelerating the construction of a healthy China and building a healthy human community.

Wang Zhizhen, vice chairman of the 11th Chinese People’s Political Consultative Conference, member of China Academy of Medical Sciences and academician of China Academy of Sciences, believes that the medical science and technology circles in China should be based on the national conditions, take the strategy of healthy China as the guide, dare to challenge the "subversive" problem, accelerate the exploration of the development path of the national modern medical science and technology innovation system, and make innovative contributions to the national medical development.

To create a good ecology of medical science and technology innovation, it is necessary to strengthen supervision. Jiao Hong, member of the 14th Chinese People’s Political Consultative Conference Standing Committee, vice chairman of the 17th Central Committee of the Agricultural Workers’ Party and director of the National Medical Products Administration, believes that entering a new stage of development, it is necessary to benchmark the world’s scientific and technological frontier, strengthen internationally advanced regulatory scientific research, and promote the modernization of drug regulatory system and regulatory capacity, so as to contribute to the high-quality development of China’s pharmaceutical industry and better protect people’s drug safety and health.

Wang Chen, vice president of China Academy of Engineering, academician of China Academy of Engineering, president of China Academy of Medical Sciences, and chairman of academic advisory committee of China Academy of Medical Sciences, believes that to create an innovative ecology of medical science and technology, we should pay attention to "four core elements", namely, academic culture, institutional system, capital resources and international environment, which are finally reflected in the subject of innovation-"people". Therefore, it is necessary to inherit the culture of medical science and technology innovation, improve the system of medical science and technology innovation, establish the mechanism of medical science and technology innovation, expand the resources of medical science and technology innovation, and create an ecological environment of medical science and technology innovation.

Wang Chen said that to create a good medical science and technology innovation ecology, we must establish a good scientific order and value orientation, strengthen academic, scientific and technological cultural construction, and build a scientific medical science and technology evaluation system; Increase investment in innovation in the field of medical health and set up a national medical health science fund as soon as possible; It is necessary to cultivate the innovation ecosystem of clinical and translational medicine and improve the scientific and technological innovation ability of hospitals.

At the same time, it is necessary to strengthen the national medical strategic scientific and technological strength, take the construction of national laboratories and the reorganization of national key laboratories as an opportunity to promote high-level scientific and technological innovation in the field of medical health, strengthen the construction of base platforms, and improve the hierarchical layout of the national medical scientific and technological innovation system; Building the National Institute of Medical Health and China Medical Health Hospital, reflecting the national will and undertaking the national mission, making them the core base and high-end strategic consulting think tank of national medical science and technology innovation, and providing support for improving the overall efficiency of national medical science and technology innovation; Pay attention to the high-level scientific and technological innovation of clinical medicine, pay attention to the cultivation of clinical medicine innovation ecosystem, and continuously enrich the resource pool of top medical scientists in China.

Wang Chen also said that China Academy of Medical Sciences will persist in facing people’s lives and health, make unremitting efforts in academic culture, institutional system, resource fund and international environment, create a fair, responsible, supportive, sustainable and dynamic ecological environment for medical science and technology innovation, promote the construction of a three-dimensional, multi-level, inclusive and cooperative national medical science and technology innovation system and core base, and strive to achieve good interaction with the international medical science and technology community, in order to achieve high-level medical science and technology self-reliance and support medical health.

Zhang Xuemin, a member of the Department of China Academy of Medical Sciences, believes that we should adhere to the correct value orientation and establish the evaluation of outstanding medical science and technology innovation, that is, what have we discovered and invented? What’s the point? Is it true and reliable? The evaluation of scientific and technological personnel should build an evaluation system that is based on "representative works", attaches importance to original innovation and major scientific discoveries, and reflects the country’s major strategic needs, breaks the scientific research routine, realizes the innovation paradigm, promotes mission-driven and interest-driven scientific and technological research with excellent scientific ecology and culture, promotes valuable, true and reliable scientific and technological innovation facing the world’s scientific and technological frontier, and promotes the development of national medical and health undertakings.

Liu Depei, a member of China Academy of Medical Sciences, believes that the core of the framework of medical science and technology innovation system is innovation elements, infrastructure, value creation and institutional environment. The layout of medical science and technology innovation system should make great efforts to promote the innovation of basic theory, the development of biomedical industry, realize the self-reliance of science and technology and improve the level of clinical diagnosis and treatment. National key laboratories, scientific research institutes, medical universities, pharmaceutical enterprises and medical institutions should cooperate with each other and combine their respective advantages to become types of subjects that play different roles. With the support of infrastructure and innovative elements, change the number of base construction, tilt the layout to clinic, coordinate the development of education, science and technology and talent elements, build basic and strategic support, and increase the investment of funds and personnel; With the high-efficiency collaborative medical science and technology innovation network, the multi-agent integrated medical science and technology innovation model is constructed, and the road of medical innovation is opened with system construction as the core, which stimulates the vitality of the main body and enhances the innovation efficiency.

Dong Erdan, a member of China Academy of Medical Sciences, believes that medical science and technology innovation has the characteristics of high risk, high public investment, inherent ethical problems and strict supervision. Therefore, we should adhere to the principle of free exploration and demand-oriented, optimize the structure and layout of medical scientific research in China, take the burden of disease and social demand as traction, solve outstanding scientific problems as driving force, and combine big data analysis to further optimize the allocation and management of medical research resources and promote the formation of a good ecological environment for medical scientific and technological innovation.

Member Wang Xiaofan, member of the Department of China Academy of Medical Sciences, pointed out that developing high-level medical science and technology is the key to building a high-level medical health cause, and it is also a hot field of international science and technology frontier competition and cooperation. In recent years, the international cooperation in medical health in China is increasing day by day, which is helpful to solve the research problems faced by biomedical research. Member Wang Xiaofan suggested further promoting international cooperation with universities, research institutes and academic groups as the main body, helping young scientists to establish more international cooperative relations, taking the lead in organizing global research projects or big science plans, taking China as the main venue, attracting global researchers to jointly study, and providing more China wisdom and Chinese programs for the development of human health.

China Medical Development Conference is an annual platform for China medical circles to discuss and plan the national medical development. Its purpose and function are to unite the national medical science and technology development ideas, lead the national medical science and technology development direction, display the important achievements of China medical science and technology, promote the national medical and health education reform, and promote the high-quality development of the national medical and health undertakings. The annual conference was held on the third weekend of April of that year, and the first conference was held in 2021, which has been held for three times so far.

通过admin

Beijing issued a yellow warning for thunder and lightning, with short-term strong winds and small hail of magnitude 7 and 8 in the local area.

According to the Beijing Meteorological Bureau, it is estimated that there will be thunderstorms in most parts of the city from 17: 00 on the 4th to 02: 00 on the 5th, with strong local short-term rain, accompanied by short-term gale and small hail of magnitude 7 and 8. Please take precautions.

Defense guide

(1) the local people’s governments at all levels, relevant departments and units shall do a good job in lightning protection according to their duties, and organize the inspection of lightning strike hidden danger units or departments;

(2) Parks, playgrounds and other open-air places should stop outdoor facilities and guide visitors to safe places;

(3) Outdoor activities (sports) such as mountaineering, sports, farming, swimming and fishing should be stopped, and buildings with lightning protection devices should be avoided in time;

(4) Don’t take shelter from the rain under big trees, stay away from tall buildings such as towers, chimneys, telephone poles, billboards, etc., don’t stay at the top of the mountain, ridges, roofs, watersides or open areas, and don’t use mobile phones;

(5) Don’t carry an umbrella in the open field, and don’t carry farm tools, badminton rackets, golf clubs, especially objects with metal on your shoulders. You should squat down in low places to reduce your body height.

通过admin

Resume: Luxinshe

  Lu Xinshe, male, Han nationality, born in November 1956 in Juye, Shandong Province, joined the Communist Party of China (CPC) in July 1985, and joined the work in August 1982. He graduated from Wuhan Institute of Water Resources and Electric Power with a bachelor’s degree in irrigation and water conservancy engineering, and is an engineer.

  1978— In 1982, he studied in the Department of Farmland Water Conservancy Engineering of Wuhan University of Water Resources and Electric Power.

  1982— In 1986, cadres of the Land Administration Bureau of the Ministry of Agriculture, Animal Husbandry and Fisheries (during this period: November 1985.11— 1986.08 Studying at the German Training Center of Northwest Agricultural University, Ministry of Agriculture, Animal Husbandry and Fisheries)

  1986— 1990 Director and Deputy Director of the Comprehensive Registry of Cadastral Management Department of the State Bureau of Land Management (during the period: 1987— In 1988, the Federal Republic of Germany Hessian Survey Bureau and Hanover Cadastral Bureau studied; 1989.02— 1989.07 Central Party School, State Organs Branch)

  1990— 1992 Deputy Director, Cadastral Management Department, State Bureau of Land Management

  1992— 1996 Director, Cadastral Management Department, State Bureau of Land Management

  1996— 1998 Deputy Director of the State Bureau of Land Management and Member of the Party Group (1995— In 1996, he was appointed as the deputy mayor of Nantong City, Jiangsu Province)

  1998— 1999 Member of the Party Group of the Ministry of Land and Resources and Director of the Department of Cultivated Land Protection

  1999— In 2009, Deputy Minister of the Ministry of Land and Resources, member of the Party Group, Director of the State Bureau of Surveying and Mapping and Party Secretary (2005— 2008) (during this period: 2000.09— 2000.11 Central Party School Provincial and Ministerial Cadre Training Class)

  2009— In 2010, Deputy Minister of the Ministry of Land and Resources, Deputy Secretary of the Party Group, and Deputy Chief Inspector of State Land

  2010— 2011 Deputy Secretary of Gansu Provincial Party Committee and President of Party School of Gansu Provincial Party Committee

  2011— 2012 Deputy Secretary of Jiangxi Provincial Party Committee and Acting Governor

  2012— 2016 Deputy Secretary and Governor of Jiangxi Provincial Party Committee

  2016— 2018 Secretary of the Jiangxi Provincial Party Committee and Director of the Standing Committee of the Provincial People’s Congress (2017.01)

  2018— In 2019, Secretary of the Party Committee of Guangxi Zhuang Autonomous Region and First Secretary of the Party Committee of Guangxi Military Region (in April 2018)

  2019.01— Secretary of the Party Committee of Guangxi Zhuang Autonomous Region, Director of the Standing Committee of the People’s Congress of the Autonomous Region, and First Secretary of the Party Committee of Guangxi Military Region.

  Alternate member of the 17th Central Committee, member of the 18th and 19th Central Committees. Deputies to the 11th, 12th and 13th National People’s Congress. Member of the 11th Party Committee of Guangxi Zhuang Autonomous Region. Representative of the 13th National People’s Congress of Guangxi Zhuang Autonomous Region.

  (People’s Network information as of January 2019)

通过admin

Reading: Post Bar Create Your Own Post Bar Tutorial Post Bar Create Your Own Post Bar Tutorial

There are so many wonderful contents in Post Bar thanks to the creation of bar owners one by one, but some users don’t know how to operate when they want to create it, so we brought a tutorial to see how to create their own Post Bar.

1, first enter your own post bar, and then click. search box .

2. Then enter the name of the bar you want and click "" Welcome to create xxx. ”。

3. Then you can click on the "" Bar directory ”。

4. After selecting the content you need, click "" accomplish ”。

5. Then click the "below" next step real-name verification ”。

6. Just submit it at last. Successfully created stickers. bar Yes.

 

通过admin

Not the flu! Recently, the symptoms are similar to those of "cold", mostly caused by this virus. ……

When I took the subway recently

It seems that more people wear masks.

Recently, many people have "cold" nasal congestion symptoms.

Many people suspect that it is the flu.

Or mycoplasma infection

In fact, apart from influenza and mycoplasma infection,

The human metapneumovirus has also quietly attacked.

What is human metapneumovirus?

What are the symptoms of infection?

Human metapneumovirus infection is increasing gradually.

Recently, the China Center for Disease Control and Prevention released the national monitoring of respiratory infectious diseases, and acute respiratory infectious diseases showed a continuous upward trend, among which human metapneumovirus infection gradually increased.

What is human metapneumovirus? Human metapneumovirus is a common virus that can cause acute respiratory infection. Compared with traditional respiratory infection viruses such as influenza, human metapneumovirus is relatively "young" and its discovery time is late. In 2001, Dutch scholars first detected the virus from nasopharyngeal aspirate samples of children with respiratory tract infection caused by unknown pathogens. Although it was discovered late, serological studies show that it has existed in humans for more than 60 years and is distributed all over the world.

How does human metapneumovirus spread? The mode of transmission of human metapneumovirus is similar to that of most respiratory viruses, mainly through the following channels:

1. droplet transmission: when an infected person coughs or sneezes, the virus will spread with droplets;

2. Contact transmission: close contact with people infected with metapneumovirus, or contact with objects contaminated by metapneumovirus (such as doorknobs, mobile phones, toys, etc.), and then touch your eyes, nose or mouth, causing the virus to enter the body.

However, it should be noted that human metapneumovirus has certain viability in the environment, especially on the surface of objects, and the virus can survive for several hours. Therefore, it is very important to do a good job in daily life.

Authorized map, reprint is risky.

This virus is easily infected by the whole population.

Human metapneumovirus usually occurs in winter and spring because it is dry and easy to spread in winter and spring. The whole population is generally susceptible to human metapneumovirus, and patients are the most contagious at the beginning of the disease. The immune protection time of patients is relatively short, and they are prone to repeated infection. It should be noted that the patient’s incubation period and terminal illness are contagious after infection.

The incubation period of human metapneumovirus infection is generally 3-6 days, and the symptoms of human metapneumovirus infection are similar to those of influenza, but the main manifestations of human metapneumovirus infection are colds, fever, cough, runny nose and other symptoms, while influenza virus will have high fever and general fatigue.

Authorized map, reprint is risky.

1. Common symptoms: upper respiratory tract infection symptoms such as cough, fever, nasal congestion and shortness of breath;

2. Mild infection: For most people, human metapneumovirus infection is a self-limited disease, and most people gradually relieve their symptoms in about 1 week;

3. Severe infection: For the following high-risk groups, human metapneumovirus may cause severe lower respiratory tract infection:

① Children under 5 years old: it may lead to bronchiolitis or severe pneumonia;

② Elderly people: It may induce lung infection or aggravate asthma;

③ People with low immunity: For example, those who receive organ transplantation or hematopoietic stem cell transplantation may have severe lung inflammation after infection.

It should be noted that at present, there are no specific drugs and vaccines for human metapneumovirus infection, and symptomatic support treatment is the main one.

During illness, it is necessary to ensure adequate energy and nutrition intake, pay attention to the balance of water and electrolyte, and maintain internal environment stability. Blind or improper use of antibacterial drugs, especially the combination of broad-spectrum antibacterial drugs, should also be avoided. Virus infection is often not complicated with bacterial infection in the early stage.

After being infected with the virus, you can pay close attention to the changes of your condition. Once you have symptoms such as dyspnea and persistent high fever, you should seek medical advice in time and use drugs rationally under the guidance of a doctor.

How to prevent human metapneumovirus infection

Because the mode of transmission of human metapneumovirus is similar to that of most respiratory viruses, we can:

Good habits: Develop good hygiene habits such as washing hands frequently, wearing masks and cleaning frequently.

Regular ventilation: open the window regularly every day to keep the indoor air fresh and unobstructed.

Less gathering: Try to avoid places where people gather or where the space is closed.

Improve immunity: eat a balanced diet, exercise moderately, work and rest regularly, and keep healthy.

Authorized map, reprint is risky.

In a word, keeping good living habits, wearing masks when going to crowded places, and taking preventive measures such as frequent hand washing, frequent ventilation and scientific disinfection can effectively reduce the chance of infection.

Want to receive more popular science knowledge in time

Set "Guangdong popular science" as a star sign ~

↓↓↓

Recommended video today

Don’t be a "mushroom" brave man

Wild mushrooms are famous for their unique delicacy and mystery.

However, there is a risk of poisoning when eating wild mushrooms.

There is a fatal hazard

There are many misunderstandings in the method of identifying poisonous mushrooms by network.

There is no shortcut to identify poisonous mushrooms.

The key to prevent poisoning is not to eat strange wild bacteria at will.

Eat bacteria rationally,

Don’t be a "mushroom" brave man

Popular reading

(Click on the picture to read)

Original title: "Not the flu! Recently, the symptoms are similar to those of "cold", mostly caused by this virus …

Read the original text